Hypertension, menstrual disorders and hormone replacement therapy (HRT) Circulatory System
Conditions
Interventions
Menopausal status was confirmed and women were randomised to one of three treatment groups or acted as controls. The treatment regimes were two oral groups, with cyclical or continuous progestagen, an
for the second three months, norethisterone was added as the progestagen, orally and transdermally as appropriate.
Measurements: Blood samples
1. fasting glucose
2. insulin
3. total cholesterol
4.
Sponsors
Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women aged 50 - 65 years from lists in general practices local to the Charing Cross Hospital Lipid Clinic in West London.
Exclusion criteria
Exclusion criteria: Women with liver, renal or endocrine abnormalities were excluded, as were those on lipid altering medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Response to HRT 2. Anthropometric measurements 3. Cardiovascular Risk Factors 4. Blood pressure 5. Lipoproteins 6. Glucose and insulin 7. Clotting variables 8. Arterial wall factors | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed